{Reference Type}: Journal Article
{Title}: Balancing Evidence and Need: Variation in US Commercial Payer Coverage of Esketamine.
{Author}: Ochigbo EB;Beinfeld MT;Chambers JD;
{Journal}: Clin Ther
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 21
{Factor}: 3.637
{DOI}: 10.1016/j.clinthera.2024.06.017
{Abstract}: <B>OBJECTIVE: </B>Variations in US commercial health plan coverage policies affect how patients access medications. Plans may vary in treatment access criteria, line of therapy, and prescriber requirements. In this study, we examined coverage of esketamine hydrochloride (Spravato) for major depressive disorder (MDD) and treatment-resistant depression (TRD) to answer the following question: how do US commercial health plans cover esketamine, and how do they guide prompt patient access to the drug?<BR><B>METHODS: </B>We used information from the Tufts Medical Center Specialty Drug Evidence and Coverage database, which includes coverage policies issued by 18 large commercial health plans in the United States. Esketamine coverage policies for MDD and TRD active in December 2022 were collated and analyzed. We compared coverage policies according to step therapy protocols, patient subgroup restrictions, and prescriber requirement criteria, evaluating patient access using the number of restrictions and proportion of plans including each criterion.<BR><B>RESULTS: </B>Plans more often imposed step therapy requirements for access to esketamine for TRD than for MDD, with line of treatment of ≤9 steps for MDD compared with 1 to 5 steps for TRD. Plans also varied with respect to the therapies they required patients to first try and experience treatment failure before granting access to esketamine for both indications. Clinical coverage requirements varied in thresholds and rating scales used to assess severity of depressive symptoms.<BR><B>CONCLUSIONS: </B>Plans vary in terms of line of therapy and clinical coverage requirements for access to esketamine. Variation in health plan coverage policies may result in inequitable access and added complexity for patients and clinicians navigating care, which may delay access to urgent treatment.<BR><B>RESULTS: </B><BR><B>UNASSIGNED: </B>Not applicable.